TAK 828

Drug Profile

TAK 828

Alternative Names: TAK-828

Latest Information Update: 16 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Class
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Crohn's disease

Most Recent Events

  • 10 May 2017 Discontinued - Phase-I for Crohn's disease (In volunteers) in USA (PO) based on results of preclinical toxicology and clinical teratogenicity studies (Takeda FY2016 Q4 results, May 2017)
  • 01 Feb 2017 Takeda terminates a phase I trial in Healthy volunteers in USA (PO, Liquid) (NCT02817516)
  • 01 Jul 2016 Takeda initiates enrolment in a phase I trial for Crohn's disease (In volunteers) in USA (NCT02817516)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top